Evidence Level:Sensitive: C3 – Early Trials
Title:
EX103, a Novel CD20xCD3 Bispecific Antibody, Showed a Favorable Safety and Potent Single-Agent Antitumor Activity in Heavily Pretreated Relapsed/Refractory Patients with B-Cell Non-Hodgkin Lymphoma
DOI:https://doi.org/10.1182/blood-2023-173486